Navigation Links
Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce fourth quarter and year ended December 31, 2010 financial results on Thursday, March 10, 2011 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 788-0543 (domestic) or (857) 350-1681 (international), participant code 73770341. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com  and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
5. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
10. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
11. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mosaic Life Care, based in St. Joseph, Missouri , has selected ... 58 clinics, located in 22 cities, and its flagship St. Joseph Medical Center. ... delivery of health care to its patients, including the insurance, billing and collections processes. ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... , March 23, 2017 ... research report created through extensive primary research (inputs ... the report aims to present the analysis of ... of Procedure (Replacement and Repair); Replacement Procedure By ... Repair By Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter ...
(Date:3/23/2017)... , March 23, 2017 ... and Healthcare disease pipeline guide Primary Hyperoxaluria - ... the Primary Hyperoxaluria (Genito Urinary System And Sex ... rare condition characterized by recurrent kidney and bladder ... substance called oxalate. Symptoms include blood in the ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from ... pillow in crowdfunding history, has established a U.S. Headquarters in New York City, ... Americans. , “We’re excited to be operating on U.S. shores, where most of our ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... for seniors, today announced rapid completion of the strategic executive team expansion needed ... notable additions to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... Monitoring Healthcare products at competitive pricing. Verisys through its FACIS ... Debarments, License restrictions and Disciplinary actions. , “We are delighted to be able ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... and non-steroidal skincare products, was awarded as winners of American Dreams & Good ... competition was hosted jointly by HSN and Good Housekeeping. , Steven Wang, ...
Breaking Medicine News(10 mins):